TY - JOUR

T1 - Экономическая эффективность длительной кислородотерапии у больных бронхолегочными заболеваниями с тяжелой хронической артериальной гипоксемией

AU - Гомон, Ю. М.

AU - Колбин, Алексей Сергеевич

AU - Титова , Ольга Николаевна

AU - Балыкина, Юлия Ефимовна

AU - Кузубова , Наталия Анатольевна

N1 - Export Date: 11 March 2024 Адрес для корреспонденции: Gomon, Y.M.; I.P. Pavlov First Saint-Petersburg State Medical University, 6-8, Lev Tolstoy str., Russian Federation; эл. почта: gomonmd@yandex.ru Пристатейные ссылки: Croxton, T.L., Bailey, W.C., Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report (2006) Am J Respir Crit Care Med, 174 (4), pp. 373-378; Doherty, D.E., Petty, T.L., Bailey, W., Recommendations of the 6th long-term oxygen therapy consensus conference (2006) Respir Care, 51 (5), pp. 519-525. , PMID: 16710952; Branson, R.D., Oxygen Therapy in COPD (2018) Respir Care, 63 (6), pp. 734-748; Titova, O.N., Kuzubova, N.A., Sklyarova, D.B., The effect of prolonged oxygen therapy on the clinical course of the disease and the function of the diaphragm in patients with chronic obstructive pulmonary disease with hypoxemic respiratory failure (three-year follow-up experience) (2019) Tuberculosis and lung diseases, 97 (9), pp. 45-51. , (in Russ)]; Smith, D., Gill, A., Hall, L., Turner, A.M., Prevalence, Pattern, Risks Factors and Consequences of Antibiotic Resistance in COPD: A Systematic Review (2021) COPD, 18 (6), pp. 672-682; Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party (1981) Lancet, 1 (8222), pp. 681-686. , PMID: 6110912; Halbert, R.J., Natoli, J.L., Gano, A., Global burden of COPD: systematic review and meta-analysis (2006) Eur Respir J, 28 (3), pp. 523-532

PY - 2023

Y1 - 2023

N2 - Background: long-term oxygen therapy (LTOT) for chronic lung diseases associated with chronic hy-poxemia is effective in terms of increasing life expectancy. However, by now, the costs of LTOT are not reimbursed by the healthcare system of the Russian Federation. Aim: to evaluate the economic efficiency of respiratory therapy centers in providing pa-tients with chronic lung diseases and severe chronic hypoxemia with LTOT at home. Patients and Methods: direct medical and nonmedical costs associated with the introduc-tion of LTOT into clinical practice were identified and calculated. Costs of LTOT, outpatient management of patients without exacerbations, treatment for exacerbations, and disability-related payments were considered. Clinical and economic modeling was performed. A cost-effectiveness analysis was performed and the budget impact was assessed. Published data and the experience of St. Petersburg Regional Respiratory Support Center were used to evaluate LTOT efficacy. Results: additional costs for LTOT per patient for 5 years are 229,759 RUB. LTOT signif-icantly (by 74%) reduce the costs of treating patients with exacerbations of chronic obstructive pulmonary disease, mainly due to a reduction in exacerbation rate, including those requiring ad-mission to hospital. Analysis of budget impact over 5 years demonstrates a decrease in direct medical costs per 100 oxygen concentrators by 32% (from 181,666,728.90 RUB to 123,247,630.82 RUB). Given mortality, the estimated number of patients opting for LTOT using 100 oxygen concentrators over 5 years is 150. Conclusions: reimbursement for LTOT costs in Russian healthcare is economically reason-able. © 2023, Meditsina-Inform LLC. All rights reserved.

AB - Background: long-term oxygen therapy (LTOT) for chronic lung diseases associated with chronic hy-poxemia is effective in terms of increasing life expectancy. However, by now, the costs of LTOT are not reimbursed by the healthcare system of the Russian Federation. Aim: to evaluate the economic efficiency of respiratory therapy centers in providing pa-tients with chronic lung diseases and severe chronic hypoxemia with LTOT at home. Patients and Methods: direct medical and nonmedical costs associated with the introduc-tion of LTOT into clinical practice were identified and calculated. Costs of LTOT, outpatient management of patients without exacerbations, treatment for exacerbations, and disability-related payments were considered. Clinical and economic modeling was performed. A cost-effectiveness analysis was performed and the budget impact was assessed. Published data and the experience of St. Petersburg Regional Respiratory Support Center were used to evaluate LTOT efficacy. Results: additional costs for LTOT per patient for 5 years are 229,759 RUB. LTOT signif-icantly (by 74%) reduce the costs of treating patients with exacerbations of chronic obstructive pulmonary disease, mainly due to a reduction in exacerbation rate, including those requiring ad-mission to hospital. Analysis of budget impact over 5 years demonstrates a decrease in direct medical costs per 100 oxygen concentrators by 32% (from 181,666,728.90 RUB to 123,247,630.82 RUB). Given mortality, the estimated number of patients opting for LTOT using 100 oxygen concentrators over 5 years is 150. Conclusions: reimbursement for LTOT costs in Russian healthcare is economically reason-able. © 2023, Meditsina-Inform LLC. All rights reserved.

KW - chronic hypoxemia

KW - cost-effectiveness analysis

KW - economic efficiency

KW - long-term oxygen therapy

KW - respiratory therapy center

U2 - 10.32364/2587-6821-2023-7-8-1

DO - 10.32364/2587-6821-2023-7-8-1

M3 - статья

VL - 7

SP - 475

EP - 481

JO - РУССКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ. МЕДИЦИНСКОЕ ОБОЗРЕНИЕ

JF - РУССКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ. МЕДИЦИНСКОЕ ОБОЗРЕНИЕ

SN - 2587-6821

IS - 8

ER -